A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

Clinical Transplantation

Volumn 23, Issue 1, 2009, Pages 23-32

  Andrés, Amado ^a   Marcén, Roberto ^b   Valdés, Francisco ^c   Sánchez Plumed, Jaime ^d   Solà, Ricard ^e   Errasti, Pedro ^f   Lauzurica, Ricardo ^g   Pallardó, Luis ^h   Bustamante, Jesús ⁱ   Amenábar, Juan José ^j   Plaza, Juan José ^k   Gómez, Ernesto ^l   Grinyó, Josep Maria ^m   Rengel, Manuel ⁿ   Puig, Josep Maria ^o   Sanz, Aurelio ^p   Asensio, Concepción ^q   Andrés, Inés ^r   Morales, J M ^a   Praga, M ^a   Ortuno de Solo B ^a   Hernandez E ^a   Gonzales E ^a   Ortuno J ^b   Pascual, J ^b   Alonso, A ^c   Fernadez C ^c   Garcia J ^d   Sanchez M A ^d   Ramos, D ^d   Beneyto, I ^d   Sainz, Z ^e   Guirado, L ^e   Diaz J M ^e   Manrique, J ^f   Rossich, E ^f   Hernandez A ^f   Bayes B ^g   Avila, A ^h   Gavela, E ^h   Sancho, A ^h   Gorriz, J L ^h   Crespo, J F ^h   Mendiluce, A ⁱ   Bralo, M B ^j   Ortega, F ^l   Suarez A ^l   Calders, A ^m   Gil Vernet, S ^m   Cruzado, J M ^m   Torras J ^m   Verde, E ⁿ   Anaya, F ⁿ   Amman, R ⁿ   Soler, J ^o   Mir, M ^o   Escuin F ^p   Jimenez C ^p   Sanchez C ^p   Bravo, J ^q   Osuna, A ^q   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e FUNDACIÓ PUIGVERT   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^j HOSPITAL DE CRUCES   (Spain)

^k Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o HOSPITAL DEL MAR   (Spain)

^p HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^r Novartis Farmaceutica SA ^*  (Spain)

more..

Author keywords

Acute rejection; Basiliximab; Cyclosporin A; Delayed graft function; Renal transplantt

Indexed keywords

ACICLOVIR; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DELAYED GRAFT FUNCTION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DELAYED GRAFT FUNCTION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63349102426     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00891.x     Document Type: Article

References (27)

1. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998: 66: 1697.
2. Oppenheimer F, Aljama P, Asensio Peinado C et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004: 19: iii11.
3. Rosengard BR, Feng S, Alfrey E et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaveric donor. Am J Transplant 2002: 2: 701.
4. Sola R, Alarcon A, Jimenez C et al. The influence of delayed graft function. Nephrol Dial Transplant 2004: 19: iii32.
5. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004: 364: 1814.
6. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: A review. Clin Transplant 2005: 19: 705.
7. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004: 4: 222.
8. Nashan B, Luck R, Kliem V et al. CMV in kidney transplantation: A single center experience over 22 years. Clin Transplant 1999: 13: 181.
9. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999: 67: 276.
10. Sheashaa HA, Bakr MA, Ismail AM et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: A three-year prospective randomized trial. J Nephrol 2003: 16: 393.
11. Kandus A, Grego K, Arnol M et al. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: Five-year single-center experience. Transplant Proc 2006: 38: 2853.
12. Vincenti F, de Andres A, Becker T et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 2006: 19: 446.
13. O pelz G, D ohler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001: 72: 1267.
14. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
15. Nankivell BJ, Gruenewald SM, Allen RDM et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995: 59: 1683.
16. Gonwa TA, Hricik DE, Brinker K et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560.
17. Ferreira AN, Machado PG, Felipe CR et al. Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results. Clin Transplant 2005: 19: 607.
18. Sennesael JJ, Bosmans JL, Bogers JP et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005: 80: 1578.
19. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006: 6: 1042.
20. Heifets M, Saeed MI, Parikh MH et al. Induction immunosuppression in kidney transplant recipients older than 60 years of age: Safety and efficacy of ATGAM, OKT3 and basiliximab. Drugs Aging 2004: 21: 747.
21. Boletis JN, Theodoropoulou H, Hiras T et al. Monoclonal antibody basiliximab with low CsA dose as initial immunosuppression. Transplant Proc 2001: 33: 3184.
22. Vincenti F, Vanrenterghem Y, N ashan B et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with CsA (low dose, low dose/ withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results. Am J Transplant 2005: 5: 539.
23. Gentil MA, Osuna A, Capdevila L et al. Spanish Kidney Transplant of Elderly Donor Study Group. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. Transplant Proc 2003: 35: 1706.
24. Kovarik J, Wolf P, Cisterne JM et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997: 64: 1701.
25. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.
26. Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006: 355: 1967.
27. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990: 323: 1723.